The cardiovascular effects of peroxisome proliferator-activated receptor agonists

American Journal of Medicine

Volumn 125, Issue 2, 2012, Pages 126-133

  Friedland, Sayuri N ^a,b   Leong, Aaron ^a,b   Filion, Kristian B ^b   Genest, Jacques ^c   Lega, Iliana C ^a,b   Mottillo, Salvatore ^a,b,d   Poirier, Paul ^e   Reoch, Jennifer ^a,b,f   Eisenberg, Mark J ^a,b,f  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Aleglitazar; Bezafibrate; Cardiovascular outcomes; Cardiovascular risk factors; Fenofibrate; Fibrates; Gemfibrozil; Pan agonists; Peroxisome proliferator activated receptor agonists; Pioglitazone; Review; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALEGLITAZAR; BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TESAGLITAZAR; TROGLITAZONE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STABLE ANGINA PECTORIS; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84856080783     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.08.025     Document Type: Review

References (58)

1. J.D. Brown, J. Plutzky Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets Circulation 115 2007 518 533 (Pubitemid 46184203)
2. A. Oyekan PPARs and their effects on the cardiovascular system Clin Exp Hypertens 33 2011 287 293
3. A. Fredenrich, P.A. Grimaldi PPAR delta: an uncompletely known nuclear receptor Diabetes Metab 31 2005 23 27 (Pubitemid 40327589)
4. B. Staels, J.C. Fruchart Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2005 2460 2470 (Pubitemid 41134276)
5. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
6. European Medicines Agency European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim Sept. 23 http://www.ema.europa.eu/docs/en-GB/ document-library/Press-release/2010/09/WC500096996.pdf Accessed December 21, 2010
7. US Food and Drug Administration FDA significantly restricts access to the diabetes drug Avandia Sept. 23 http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm Accessed December 21, 2010
8. S. Abourbih, K.B. Filion, L. Joseph Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review Am J Med 122 2009 962.e961 962.e968
9. C. Patel, K.L. Wyne, D.K. McGuire Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2 2005 61 66 (Pubitemid 40826997)
10. S.E. Nissen, K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
11. Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada 2008 Canadian Diabetes Association Toronto, Ontario
12. J.A. Dormandy, B. Charbonnel, D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
13. R. Wilcox, M.G. Bousser, D.J. Betteridge Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke 38 2007 865 873 (Pubitemid 46568445)
14. E. Erdmann, J.A. Dormandy, B. Charbonnel The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study J Am Coll Cardiol 49 2007 1772 1780 (Pubitemid 46629127)
15. P. Gaede, H.H. Parving, O. Pedersen PROactive study Lancet 367 2006 23 24 author reply 26-27
16. J.S. Yudkin, N. Freemantle PROactive study Lancet 367 2006 24 25 author reply 26-27
17. S.E. Nissen, S.J. Nicholls, K. Wolski Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes JAMA 299 2008 1561 1573 (Pubitemid 351482795)
18. US Food and Drug Administration Actos (pioglitazone): ongoing safety reviewpotential increased risk of bladder cancer Sept. 17 http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226257. htm Accessed July 18, 2011
19. European Medicines Agency Update on ongoing European review of pioglitazonecontaining medicines http://www.ema.europa.eu/docs/en-GB/document- library/Press-release/2011/06/WC500107515.pdf Accessed July 18, 2011
20. Caisse nationale de l'assurance maladie Risque de cancer de la vessie chez les personnes diabtiques traites par pioglitazone en France: une tude de cohorte sur les donnes du SNIIRAM et du PMSI http://www.afssaps.fr/var/afssaps- site/storage/original/application/b42a6bf9a1b63c3dbec7388d3914687b.pdf Accessed July 18, 2011
21. Agence franaise de scurit sanitaire des produits de sant Communiqu de presse: Suspension de l'utilisation des mdicaments contenant de la pioglitazone (Actos®, Competact®) www.afssaps.fr/content/download/34031//cp-110609- Pioglitazone.pdf Accessed July 18, 2011
22. Das Bundesinstitut fr Arzneimittel und Medizinprodukte Das BfArM rt derzeit vom Gebrauch pioglitazonhaltiger Arzneimittel ab http://www.bfarm.de/DE/ BfArM/Presse/mitteil2011/pm05-2011.html Accessed July 18, 2011
23. H.C. Gerstein, S. Yusuf, J. Bosch Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
24. A.J. Scheen [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease] Rev Med Liege 61 2006 728 732 (Pubitemid 46381741)
25. S.E. Kahn, S.M. Haffner, M.A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443 (Pubitemid 44903747)
26. G.A. Diamond, L. Bax, S. Kaul Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death Ann Intern Med 147 2007 578 581 (Pubitemid 351664507)
27. P.D. Home, S.J. Pocock, H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomesan interim analysis N Engl J Med 357 2007 28 38 (Pubitemid 47026732)
28. P.D. Home, S.J. Pocock, H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
29. J. Avorn Keeping science on top in drug evaluation N Engl J Med 357 2007 633 635 (Pubitemid 47267231)
30. D.M. Nathan, J.B. Buse, M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
31. D.L. Bhatt, D.P. Chew, C. Grines Peroxisome proliferator-activated receptor [gamma] agonists for the Prevention of Adverse events following percutaneous coronary Revascularizationresults of the PPAR Study Am Heart J 154 2007 137 143 (Pubitemid 46920478)
32. E.M. Lonn, H.C. Gerstein, P. Sheridan Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) J Am Coll Cardiol 53 2009 2028 2035
33. H.C. Gerstein, R.E. Ratner, C.P. Cannon Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease Circulation 121 2010 1176 1187
34. S.E. Nissen, K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Intern Med 170 2010 1191 1201
35. C.J. Rosen Revisiting the rosiglitazone storylessons learned N Engl J Med 363 2010 803 806
36. E. Blind, K. Dunder, P. de Graeff Rosiglitazone: a European regulatory perspective Diabetologia 54 2011 213 218 Epub 2010 Dec 14
37. US Food and Drug Administration FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl May 18 http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm Accessed May 18, 2011
38. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
39. Hln. Duez, B. Lefebvre, P. Poulain Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation Arterioscler Thromb Vasc Biol 25 2005 585 591 (Pubitemid 40315682)
40. K.S. Frederiksen, E.M. Wulff, P. Sauerberg Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles J Lipid Res 45 2004 592 601 (Pubitemid 38338007)
41. H.T. Xavier [Drug combinations: statins and fibrates] Arq Bras Cardiol 85 Suppl 5 2005 34 35
42. A. Keech, R.J. Simes, P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
43. R. Scott, J. Best, P. Forder Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] Cardiovasc Diabetol 4 2005 13
44. R. Scott, R. O'Brien, G. Fulcher Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
45. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
46. J.B. Buse Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods Am J Cardiol 99 2007 S21 S33
47. M.H. Frick, O. Elo, K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245 (Pubitemid 17147964)
48. H.B. Rubins, S.J. Robins, D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418 (Pubitemid 29362514)
49. A. Tenenbaum, M. Motro, E.Z. Fisman Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons Cardiovasc Diabetol 4 2005 14
50. P. Balakumar, M. Rose, M. Singh PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80 2007 1 10 (Pubitemid 47013361)
51. R.S. Elkeles, J.R. Diamond, C. Poulter Cardiovascular outcomes in type 2 diabetes A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Diabetes Care 21 1998 641 648 (Pubitemid 28172949)
52. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
53. A. Tenenbaum, M. Motro, E.Z. Fisman Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med 165 2005 1154 1160 (Pubitemid 40720740)
54. S.E. Nissen, K. Wolski, E.J. Topol Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus JAMA 294 2005 2581 2586 (Pubitemid 41697247)
55. M.B. Oleksiewicz, I. Thorup, H.S. Nielsen Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo Toxicol Pathol 33 2005 552 560 (Pubitemid 41473090)
56. R.E. Ratner, S. Parikh, C. Tou Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes Diab Vasc Dis Res 4 2007 214 221 (Pubitemid 47529211)
57. R.R. Henry, A.M. Lincoff, S. Mudaliar Effect of the dual peroxisome proliferator-activated receptor-[alpha]/[gamma] agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 2009 126 135
58. B. Charbonnel PPAR-[alpha] and PPAR-[gamma] agonists for type 2 diabetes Lancet 374 2009 96 98